

Ravindra (Ravi) Majeti MD, PhD

Stanford University
Department of Medicine
Division of Hematology
Cancer Institute
Institute for Stem Cell Biology and Regenerative Medicine

Lokey Stem Cell Building
265 Campus Drive, G3021B
Stanford, CA 94305
(ph) 650-721-6376
rmajeti@stanford.edu
<http://majetilab.stanford.edu>

Positions, Education, and Training

Associate Professor of Medicine, Division of Hematology – Stanford University	2015-current
Assistant Professor of Medicine, Division of Hematology – Stanford University	2009-2015
Instructor in Medicine, Division of Hematology - Stanford University	2007-2009
Fellowship in Hematology - Stanford University, Stanford, CA	2004-2007
Residency in Internal Medicine - Brigham & Women's Hospital, Boston, MA	2002-2004
MD - University of California, San Francisco (UCSF), San Francisco, CA	June 2002
PhD in Biomedical Sciences - UCSF, San Francisco, CA	August 2000
AB in Biochemical Sciences - Harvard University, Cambridge, MA	June 1994

Leadership Positions

Stanford Medicine Leadership Academy	2014-2015
Assistant Director, Stanford Ludwig Center for Cancer Stem Cell Research	2014-current
Co-Director Lymphoma and Leukemia Program, Stanford Cancer Center	2014-current
Director, Translational Program in Hematologic Malignancies	2013-current
Co-Director Stanford Clinical Investigator Pathway, Internal Medicine Residency	2013-current

Honors

Leukemia and Lymphoma Society – Scholar Award	2015
New York Stem Cell Foundation – Robertson Stem Cell Investigator	2011
Stinehart/Reed Award – Stanford Institute for Stem Cell Biology	2009
AACR Centennial Post-Doctoral Fellowship	2008
Burroughs Wellcome Fund Career Award for Medical Scientists	2008
Helen Hay Whitney Fellowship (declined)	2006
Walter and Idun Berry Fellowship – Stanford University	2005
Amgen Hematology/Oncology Fellowship	2005
Medical Student Achievement Award - American College of Rheumatology	2000
Trefethen Award – UCSF	2000
MSTP Fellowship – UCSF	1994
Summa Cum Laude - Harvard College	1994
Phi Beta Kappa - Harvard College	1994

Professional Societies, License, and Certification

American Board of Internal Medicine – Subspecialty Certification in Hematology	2007
American Board of Internal Medicine – Diplomate in Internal Medicine	2005
Medical Board of California – Physician and Surgeon License	2004-current
American Society of Hematology	2004-current
American Association for Cancer Research	2010-current
International Society for Stem Cell Research	2010-current
American Society of Hematology, Myeloid Neoplasia Scientific Committee	2013-2014
Ad Hoc Member, Molecular and Cellular Hematology NIH Study Section	2014

Publications

1. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces-Zimmerman MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, and **Majeti R**. *Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation*. Cell Stem Cell, 17: 675-688 (2015)
2. Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, and **Majeti R**. *Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia*. Exp Hematology, 43: 989-992 (2015)
3. Jung N*, Dai B*, Gentles AJ, **Majeti R***, and Feinberg A*. *An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis*. Nat Communications, 7: 8489 (2015)
4. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL*, and **Majeti R***. *Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential*. PLoS One, 10: e0137345 (2015)
5. Reinisch A, Chan SM, Thomas D, and **Majeti R**. *Biology and clinical relevance of acute myeloid leukemia stem cells*. Semin Hematol, 52: 150-164 (2015)
6. Piccione EC, Juarez S, Liu J, Tseng S, Ryan C, Narayanan C, Wang L, Weiskopf K, and **Majeti R**. *A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells*. MAbs, 7: 946-956 (2015)
7. McClellan JS*, Dove CG*, Gentles AJ, Ryan CE, and **Majeti R**. *Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages*. P.N.A.S., 112: 4074-4079 (2015)
8. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo, I Weissman IL, Minary P, **Majeti R**, Constantinescu SN, Piehler J, and Garcia KC. *Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands*. Cell, 160: 1196-1208 (2015)
9. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, and **Majeti R**. *Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia*. Nature Medicine, 21: 178-184 (2015)
10. Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL*, **Majeti R***. *Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition*. Blood, 125: 316-326 (2015)
11. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, **Majeti R**, Strunk D. *Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation*. Blood, 125: 249-260 (2015)
12. **Majeti R**. *Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia*. Best Pract Res Clin Haematol, 27: 229-234 (2014)
13. Corces-Zimmerman MR and **Majeti R**. *Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis*. Leukemia, 28: 2276-82. (2014)
14. Chao MP, Hong J, Kunder C, Lester L, Schrier SL, and **Majeti R**. *Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss Syndrome responsive to eculizumab*

and rituximab. Am J Hematol, 90: 78-81 (2015)

15. Green MR, Vicente-Duenas C, Romero-Camarero I, Long Liu C, Dai B, Gonzalez-Herrero I, Garcia-Ramirez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jimenez R, Martinez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, **Majeti R**, Melnick A, Cobaleda C, Alizadeh AA, and Sanchez-Garcia I. *Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.* Nat Commun, 5: 3904 (2014).
16. Nguyen LX, Chan SM, Ngo TD, Raval A, Kim KK, **Majeti R**, and Mitchell BS. *Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.* Blood, 124: 579-589 (2014)
17. Lee JY, Hong W, **Majeti R**, and Stearns T. *Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.* PLoS One, 9: e92641 (2014)
18. Corces-Zimmerman MR, Hong W, Weissman IL, Medeiros BC, and **Majeti R**. *Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.* P.N.A.S., 111: 2548-2553 (2014)
19. Chan SM and **Majeti R**. *Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.* International Journal of Hematology, 98: 648-657 (2013)
20. Huang M, Thomas D, Li MX, Feng W, Chan SM, **Majeti R**, and Mitchell BS. *Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.* Leukemia, 27: 1970-1980 (2013)
21. McClellan JS and **Majeti R**. *The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould.* EMBO Mol Med, 5: 7-9 (2013)
22. Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivery A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, Davies B, Price A, Wall K, Griffiths M, Cavenagh J, **Majeti R**, Weissman I, Burnett A, and Vyas P. *Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.* Leukemia, 27: 1028-1036 (2012)
23. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL*, Quake SR*, and **Majeti R***. *Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.* Science Translational Medicine, 4: 149ra118 (2012)
24. Ochsenreither S, **Majeti R**, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, and Greenberg P. *Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.* Blood, 119: 5492-5501 (2012)
25. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, **Majeti R**, West RB, Fletcher JA, Beck AH, Weissman IL, and van de Rijn M. *Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.* P.N.A.S., 109: 6656-6661 (2012)
26. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, **Majeti R**, Harsh GR van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, and Weissman IL. *The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors.* P.N.A.S., 109: 6662-6667 (2012)

27. Jan M and **Majeti R**. *Clonal evolution of acute leukemia genomes*. Oncogene, 10: 135-140 (2012)
28. Chao MP, Weissman IL*, and **Majeti R***. *The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications*. Current Opinion in Immunology, 24: 225-32 (2012)
29. Chao MP, **Majeti R***, and Weissman IL*. *Programmed cell removal: a new obstacle in the road to developing cancer*. Nature Reviews Cancer, 12: 58-67 (2011)
30. McClellan JS, Kohrt HE, Coutre SS, Gotlib JR, **Majeti R**, Alizadeh AA, and Medeiros BC. *Treatment advances have not improved the early death rate in acute promyelocytic leukemia*. Haematologica, 97: 133-136 (2012)
31. Alizadeh AA and **Majeti R**. *Surprise! HSC are aberrant in chronic lymphocytic leukemia*. Cancer Cell, 20: 135-6 (2011)
32. Chao MP, Tang C, Pachynski RK, Chin R, **Majeti R***, and Weissman IL*. *Extra-nodal dissemination of non-Hodgkin's lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy*. Blood, 118: 4890-4901 (2011)
33. Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP*, and **Majeti R***. *Single cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments*. Blood, 117: 4226-4233 (2011)
34. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, and **Majeti R**. *Prospective separation of normal and leukemia stem cells based on differential expression of TIM3, a human AML stem cell marker*. P.N.A.S., 108: 5009-5014 (2011)
35. **Majeti R** and Weissman IL. *Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye*. Cancer Cell, 19: 9-10 (2011)
36. Gentles AJ, Plevritis SK, **Majeti R***, and Alizadeh AA*. *Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia*. JAMA, 304: 2706-15 (2010)
37. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, **Majeti R***, and Weissman IL*. *Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47*. Sci Transl Med, 2: 63ra94 (2010)
38. **Majeti R**. *Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells*. Oncogene, 30:1009-19 (2011)
39. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL*, and **Majeti R***. *Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia*. Cancer Res, 1:1374-84 (2011)
40. Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, **Majeti R**, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, and Medeiros BC. *Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience*. Am J Hematol, 85: 877-81 (2010)
41. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL*, and **Majeti R***. *Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin Lymphoma*. Cell, 142: 699-713 (2010)
42. Diehn, M and **Majeti R**. *Metastatic cancer stem cells: an opportunity for improving cancer treatment?*

Cell Stem Cell, 6: 502-503 (2010)

43. Jaiswal S, Chao MP, **Majeti R**, and Weissman IL. *Macrophages as mediators of tumor immunosurveillance*. Trends Immunol, 31: 212-219 (2010)
44. Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, **Majeti R**, Kogel KE, Azar CA, Patel S, and Alizadeh AA. *Immunophenotypic features of acute myeloid leukemia with $inv(3)(q21;q26.2)/t(3;3)(q21;q26.2)$* . Leukemia Research, 34: 594-597 (2010)
45. **Majeti R***, Chao MP*, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, and Weissman IL. *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*. Cell, 138: 286-299 (2009)
46. Jaiswal S, Jamieson CHM, Pang WW, Park, CY, Chao MP, **Majeti R**, Traver D, van Rooijen N, and Weissman IL. *CD47 is up-regulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis*. Cell, 138: 271-285 (2009)
47. **Majeti R***, Becker MW*, Tian Q*, Lee M, Yan X, Liu R, Chiang J, Clarke MF, Hood, L, and Weissman IL. *Dysregulated gene expression networks in human acute myelogenous leukemia stem cells*. P.N.A.S., 106: 3396-3401 (2009)
48. Ooi AGL, Karsunky H, **Majeti R**, Butz S, Vestweber D, Ishida T, Quertermous T, Weissman IL, and Forsberg EC. *The adhesion molecule ESAM1 is a novel hematopoietic stem cell marker*. Stem Cells, 27: 653-661 (2009)
49. Park CY*, **Majeti R***, and Weissman IL. *In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood*. Nature Protocols, 3: 1932-1940 (2008)
50. **Majeti R***, Park CY*, and Weissman IL. *Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood*. Cell Stem Cell, 1:635-645 (2007)
51. Hermiston ML, Tan AL, Gupta VA, **Majeti R**, and Weiss A. *The juxtamembrane wedge negatively regulates CD45 function in B cells*. Immunity, 23: 635-647 (2005)
52. Hermiston ML, Xu Z, **Majeti R**, and Weiss A. *Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases*. J. Clin. Invest., 109: 9-14 (2002)
53. **Majeti R** and Weiss A. *Regulatory mechanisms for receptor protein tyrosine phosphatases*. Chemical Reviews, 101: 2441-2448 (2001)
54. Baker JE, **Majeti R**, Tangye SG, and Weiss A. *Protein tyrosine phosphatase CD148-mediated inhibition of T cell receptor signal transduction occurs through the reduction of LAT and PLC-g phosphorylation*. Mol. Cell. Bio., 21: 2393-2403 (2001)
55. **Majeti R**, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, and Weiss A. *An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity*. Cell, 103: 1059-1070 (2000)
56. Lagunoff M, **Majeti R**, Weiss A, and Ganem D. *Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus*. P.N.A.S., 96: 5704-5709 (1999)
57. **Majeti R**, Bilwes AM, Noel JP, Hunter T, and Weiss A. *Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge*. Science, 279: 88-91 (1998)

Note: * indicates equal authorship

Abstracts

1. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces-Zimmerman MR, Buenrostro J, Chan SM, Thomas D, Koenig J, Hong WJ, Chang H, and **Majeti R**. *Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation*. Blood (ASH Annual Meeting Abstracts) 126:841 (2015) (Selected for Oral Presentation)
2. Sinha S, Thomas D, Chan S, Gao Y, Jansen R, **Majeti R**, and Dill D. *Boolean Implication Mining for Synthetic Lethal Interactions in AML Identifies Acetyl-CoA Carboxylase as a Synthetic Lethal Partner of the IDH1 Mutation*. Blood (ASH Annual Meeting Abstracts) 126:1404 (2015)
3. Thomas D, Sinha S, Yu L, Jung N, Dai B, Gentles A, Feinberg AP, Dill D, and **Majeti R**. *Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition*. Blood (ASH Annual Meeting Abstracts) 124:780 (2014) (Selected for Oral Presentation)
4. Reinisch A, Gratzinger D, Hong WJ, **Majeti R**. *A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoietic Cells and Reveals Myelofibrosis-Initiating Cells in the HSC Compartment*. Blood (ASH Annual Meeting Abstracts) 124:349 (2014) (Selected for Oral Presentation)
5. Corces-Zimmerman MR, Eaton M, Lopez J, Ke N, Fritz C, Olson E, **Majeti R**, and Loven J. *Discovery and Characterization of Super-Enhancer-Associated Dependencies in Acute Myeloid Leukemia*. Blood (ASH Annual Meeting Abstracts) 124:3539 (2014)
6. Chan SM, Thomas D, Medeiros BC, and **Majeti R**. *Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function*. Blood (ASH Annual Meeting Abstracts) 124:615 (2014) (Selected for oral presentation)
7. Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo CD, Daver N, **Majeti R**, Andreeff M, Chan SM, and Konopleva M. *Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia*. Blood (ASH Annual Meeting Abstracts) 124:3763 (2014)
8. Mazumdar C, Li R, Buenrostro J, Chang H, and **Majeti R**. *Cohesin Complex Mutations Impair Differentiation of Human Hematopoietic Stem and Progenitor Cells*. Blood (ASH Annual Meeting Abstracts) 124:4785 (2014)
9. Reinisch A and **Majeti R**. *An in vivo model of primary myelofibrosis using a humanized bone marrow niche reveals disease-initiating cells in the CD34+/CD38-/CD90+ hematopoietic compartment*. International Society for Experimental Hematology, 2014 Annual Meeting. (Selected for oral presentation).
10. Sinha S, Thomas D, Gentles A, Yu L, Jung N, Feinberg A, Dill D, and **Majeti R**. *Integrative Analysis of TCGA Data Reveals Wilms' Tumor 1 Mutation is a Driver of DNA Methylation in Acute Myeloid Leukemia*. TCGA Third Annual Scientific Symposium. (Selected for oral presentation)
11. Sinha S, Thomas D, Yu L, Jung N, Gentles A, Feinberg A, Dill D, and **Majeti R**. *Wilms' Tumour Mutation is a Driver of DNA Hypermethylation in Acute Myeloid Leukemia*. Keystone Symposia - Cancer Epigenetics Q1 #3037. (Selected for oral presentation)
12. Thomas D, Sinha S, Yu L, Jung N., Gentles A, Feinberg A, Dill D, and **Majeti R**. *Boolean Implications Identify Wilms' Tumour 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia*. New Directions in Leukemia Research (NDLR 2014); Noosa, Queensland, Australia. (Selected for oral presentation)

13. Sinha S, Thomas D, Yu L, Jung N, Gentles A, Feinberg A, Dill D, and **Majeti R.** *Wilms' Tumour 1 Mutation is a Driver of DNA Hypermethylation in Acute Myeloid Leukemia.* Biomedical Computation at Stanford 14th Annual Symposium (BACTS 2014)
14. Corces-Zimmerman MR, Hong WJ, and **Majeti R.** *Mutations in Genes Regulating the Epigenome Occur Early During the Evolution of Human AML and Persist During Remission.* *Keystone Symposia - Cancer Epigenetics Q1*, 1047 (2014)
15. McClellan JS, Gentles AJ, Ryan CE, and **Majeti R.** *Transdifferentiation of Human Philadelphia Chromosome-Positive B Cell Acute Lymphoblastic Leukemia Cells into Non-Leukemic Macrophages.* Blood (ASH Annual Meeting Abstracts) 122:1430 (2013)
16. Chan SM, Medeiros BC, and **Majeti R.** *BCL-2 Inhibition as a Synthetic Lethal Approach to Target Isocitrate Dehydrogenase Mutations in Acute Myeloid Leukemia Stem Cells.* Blood (ASH Annual Meeting Abstracts) 122:885 (2013) (Selected for oral presentation)
17. Nguyen LT, Huang M, Chan SM, **Majeti R.**, and Mitchell BS. *Activation Of Akt Enhances Ribosomal RNA Synthesis In AML Cells Through a Novel Isoform Of TIF-1A and Inhibition Of Filamin A Cleavage.* Blood (ASH Annual Meeting Abstracts) 122:1266 (2013)
18. Jan M, Synder TM, Corces-Zimmerman MR, Weissman IL, Quake SR, and **Majeti R.** *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML.* American Association of Cancer Research, 103rd Annual Meeting (2012)
19. Jan M, Synder TM, Corces-Zimmerman MR, Weissman IL, Quake SR, and **Majeti R.** *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML.* Blood (ASH Annual Meeting Abstracts) 118:4 (2011) (Selected for oral presentation)
20. Craddock C, Goardon N, Quek L, Freeman S, Siddique S, Raghavan M, Schuh A, Grimwade D, Hills RK, Brookes C, Griffiths M, Cavenagh JD, **Majeti R.**, Weissman IL, Burnett AK, and Vyas P. *Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia.* Blood (ASH Annual Meeting Abstracts) 118:638 (2011)
21. Jan M, Alizadeh AA, Chao MP, Cha AC, Sahoo D, Weissman IL, and **Majeti R.** *TIM-3 Is a Novel Human Acute Myeloid Leukemia Marker that Enables the Prospective Separation of Normal and Leukemia Stem Cells.* ISSCR 8th Annual Meeting (2010)
22. Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, Levy R, Weissman IL, and **Majeti R.** *Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts.* Blood (ASH Annual Meeting Abstracts) 114:2716 (2009)
23. Gibbs K, Gilbert P, Weissman IL, Blau HM, Nolan GP, and **Majeti R.** *Single Cell Phospho-Flow Analysis of Cytokine Stimulation in Human Hematopoietic Progenitors Reveals That G-CSF Acts Directly On Human Hematopoietic Stem Cells.* Blood (ASH Annual Meeting Abstracts) 114:3617 (2009)
24. Alizadeh AA, McClellan JS, Gotlib JR, Coutre S, **Majeti R.**, Kohrt HE, and Medeiros BC. *Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.* Blood (ASH Annual Meeting Abstracts) 114: 1015 (2009)
25. Kohrt HE, Patel S, Ho M, Owen T, **Majeti R.**, Gotlib JR, Coutre S, Medeiros BC, and Alizadeh AA. *Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).* Blood (ASH Annual Meeting Abstracts) 114: 1617 (2009)

Oral Presentations

1. Hematological Malignancies: From Mechanisms to Therapy, Milan, Italy 2016
Title: *Pre-Leukemic Hematopoietic Stem Cells in Human AML*
2. 5th International Workshop on Humanized Mice, Zurich, Switzerland 2016
Title: *A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoiesis*
3. American Society of Hematology, 2015 Annual Meeting Scientific Program 2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
4. 8th International Conference on WT1 in Human Neoplasia 2015
Title: *Mutant WT1 is Associated with DNA Hypermethylation of PRC2 Targets in AML and Responds to EZH2 Inhibition*
5. Society of Hematologic Oncology, 2015 Annual Meeting 2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
6. ESH International Conference on AML 2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
7. ESH International Conference on AML 2015
Title: *IDH1/2 Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia*
8. Working Conference on the Classification and Nomenclature of Clonal Conditions – Vienna 2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
9. European Hematology Association, 2015 Annual Meeting, Plenary Session 2015
Title: *Tracking and Targeting Leukemia Stem Cells*
10. International Society for Experimental Hematology - Webinar 2015
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
11. 7th Biennial Workshop, Clinical Translation of Epigenetics in Cancer Therapy 2015
Title: *Mutant WT1 is Associated with DNA Hypermethylation of PRC2 Targets in AML and Responds to EZH2 Inhibition*
12. 2014 WAFSF on Stem Cell Research and Regenerative Medicine 2014
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells*
13. AACR Hematologic Malignancies, Philadelphia 2014
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells*
14. International Society for Experimental Hematology, Annual Meeting, Montreal 2014
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
15. Leukemia and Lymphoma Society, Annual Scientific Meeting 2014
Title: *A Bispecific Antibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing NHL Cells*
16. Acute Leukemia Forum 2014, San Francisco 2014
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
17. 8th Sino-US Symposium on Medicine in the 21st Century, Shanghai, China 2013
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Malignancies*

18. Nature Biotechnology SciCafe, San Francisco 2013
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
19. 2013 Annual Meeting, Japanese Society of Hematology 2013
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
20. 2nd International Michelangelo Conference, Milan, Italy 2013
Title: *Antibody Therapy Targeting CD47*
21. 1st Annual, Shanghai International Workshop on Stem Cells and Cancer 2013
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
22. 2013 BMT Tandem Meetings 2013
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
23. Charles Rodolphe Brupbacher Symposium, Zurich 2013
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
24. American Society of Hematology, Myeloid Workshop 2012
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody for the Treatment of AML*
25. Regenerative Medicine Seminar Series, Stanford University 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
26. DKFZ, 2nd Symposium, Targeted Cancer Therapy 2012
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
27. DGHO Hematology-Oncology, Annual Meeting – Plenary Session 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
28. New York Stem Cell Foundation, Annual Meeting 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
29. American Society of Clinical Oncology, Annual Meeting 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
30. Integrative Cancer Biology Program, NCI Steering Committee Meeting 2012
Title: *Identification of Key Drivers of Human AML Stem Cell Pathogenesis*
31. Center for Cancer Systems Biology, 2nd Annual Symposium, Stanford University 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
32. American Association for Cancer Research, 103rd Annual Meeting 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
33. American Society of Hematology, 53rd Annual Meeting – Plenary Session 2011
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
34. USP Conference on Stem Cells, Sao Paulo, Brazil 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
35. 20th Anniversary Symposium of GRAN, Tokyo, Japan 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
36. Stem Cell Research Symposium, Kyushu University 2011

Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Malignancies*

37. 2nd Meeting, Experimental Hematology, CEINGE, Naples, Italy 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
38. European Hematology Association, 16th Annual Meeting 2011
Title: *Monoclonal Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells*
39. Center for Cancer Systems Biology, 1st Annual Symposium, Stanford University 2011
Title: *Computational and Functional Approaches to Investigation of Leukemia Stem Cells in AML*
40. American Association for Cancer Research, 102nd Annual Meeting 2011
Title: *Therapeutic Targeting of Cancer Stem Cell Survival Mechanisms*
41. American Association for Cancer Research, 102nd Annual Meeting 2011
Title: *Isolation of Normal Hematopoietic Stem Cells and Acute Myeloid Leukemia Stem Cells*
42. CIRM-inStem Collaborative Meeting 2011
Title: *Clinical Significance and Prospective Separation of Leukemia Stem Cells in AML*
43. City of Hope, Innovative Partnerships: Bringing Stem Cell Discoveries to the Clinic 2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
44. NHLBI, Progenitor Cell Biology Consortium Meeting 2010
Title: *Single Cell Phospho-Flow Cytometry Reveals Human HSC Respond Directly to Numerous Cytokines*
45. Japanese Society of Hematology, 72nd Annual Meeting 2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
46. Intl Conference, Stem Cells: the Diverging Goals of Regenerative Medicine and Oncology 2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
47. American Association for Cancer Research, 101st Annual Meeting 2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
48. 17th International Molecular Medicine Tri-Conference 2010
Title: *CD47: An Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells*
49. International Society for Stem Cell Research, 8th Annual Meeting 2010
Title: *TIM-3 Is a Novel Human Acute Myeloid Leukemia Marker that Enables the Prospective Separation of Normal and Leukemia Stem Cells*
50. IBC 20th Annual International Conference, Antibody Engineering 2009
Title: *Blocking monoclonal antibodies directed against CD47 preferentially enable phagocytosis and elimination of human acute myeloid leukemia stem cells*
51. AACR-NCI-EORTC Conference, Molecular Targets and Cancer Therapeutics 2009
Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
52. Keystone Meeting, Antibodies as Drugs 2009
Title: *Blocking monoclonal antibodies directed against CD47 preferentially enable phagocytosis and elimination of human acute myeloid leukemia stem cells*

53. American Society of Hematology, 50th Annual Meeting 2008
Title: *CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
54. Gordon Research Conference, Stem Cells and Cancer 2007
Title: *Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood*
55. American College of Rheumatology, 64th Annual Meeting, Plenary Session 2000
Title: *An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity*
56. Keystone Meeting, Signaling 2000 1998
Title: *Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge*

Invited Seminars

1. Agios Pharmaceuticals, Cambridge, MA 2015
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
2. Dana Farber Cancer Institute, BMT Grand Rounds 2015
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
3. Cleveland Clinic, Stem Cell Institute 2015
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
4. MD Anderson Cancer Center, Leukemia Grand Rounds 2014
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
5. Albert Einstein School of Medicine – Stem Cell Institute 2013
Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
6. University of California, San Francisco – Cancer Center 2013
Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
7. University of Texas, Southwestern – Children’s Research Institute 2012
Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
8. PACTTE/NHLBI – Webinar 2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
9. Agilent Technologies, Santa Clara, California 2012
Title: *Characterization of Normal HSC and AML Stem Cells*
10. Epply Institute, University of Nebraska – Omaha, Cancer Short Course 2012
Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
11. American Association of Clinical Chemistry, Southern California Section 2012
Title: *Clinical Significance, Isolation, and Targeting of Leukemia Stem Cells in AML*
12. Chinese American Biopharmaceutical Society, Foster City, California 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
13. Memorial Sloan Kettering Cancer Center, New York, New York 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
14. Pfizer (Rinat), South San Francisco, California 2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
15. LSU Cancer Center, New Orleans, Louisiana 2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
16. MD Anderson Cancer Center, Houston, Texas 2010
Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
17. Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom 2009
Title: *CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
18. Genentech, Inc., South San Francisco, California 2009

Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*